Tonix Pharmaceuticals Holding (TNXP) EBITDA (2011 - 2026)
Tonix Pharmaceuticals Holding (TNXP) posted quarterly EBITDA of -$41.5 million for Q1 2026, down 158.73% year-over-year from $70.7 million in Q1 2025, and up 13.98% quarter-over-quarter from -$48.3 million in Q4 2025.
Tonix Pharmaceuticals Holding (TNXP) EBITDA (2011 - 2026) Analysis & Trends
Tonix Pharmaceuticals Holding's EBITDA history runs 16 years deep, the most recent figure standing at -$41.5 million for Q1 2026.
- In Q1 2026, EBITDA fell 158.73% year-over-year to -$41.5 million; the TTM figure through Mar 2026 stood at -$151.2 million (down 15.05% YoY), while the FY2025 annual figure was -$125.7 million, up 8.05% from the prior year.
- EBITDA for Q1 2026 stood at -$41.5 million, up from -$48.3 million in the prior quarter.
- The five-year high for EBITDA was -$15.6 million in Q3 2024, with the low at -$77.3 million in Q2 2024.
- The 5-year median for EBITDA is -$28.3 million (2025), against an average of -$31.4 million.
- The sharpest annual moves came in 2024 and 2025: EBITDA slumped 166.59% in 2024, then jumped 63.4% in 2025.
- Tonix Pharmaceuticals Holding's EBITDA stood at -$32.7 million in 2022, then grew by 16.5% to -$27.3 million in 2023, then grew by 17.74% to -$22.5 million in 2024, then sank by 114.8% to -$48.3 million in 2025, then gained by 13.98% to -$41.5 million in 2026.
- Business Quant data shows TNXP's EBITDA at -$41.5 million in Q1 2026, -$48.3 million in Q4 2025, and -$33.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Tonix Pharmaceuticals Holding | 213.43 Mn | 213.43 Mn | 12.84 Mn | -42.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -42.54 Mn |
| Mar 31, 2026 | -41.54 Mn |
| Dec 31, 2025 | -48.29 Mn |
| Sep 30, 2025 | -33.07 Mn |
| Jun 30, 2025 | -28.30 Mn |
| Mar 31, 2025 | -16.05 Mn |
| Dec 31, 2024 | -22.48 Mn |
| Sep 30, 2024 | -15.55 Mn |
| Jun 30, 2024 | -77.32 Mn |
| Mar 31, 2024 | -21.35 Mn |
| Dec 31, 2023 | -27.33 Mn |
| Sep 30, 2023 | -28.15 Mn |
| Jun 30, 2023 | -29.00 Mn |
| Mar 31, 2023 | -33.90 Mn |
| Dec 31, 2022 | -32.73 Mn |
| Sep 30, 2022 | -29.59 Mn |
| Jun 30, 2022 | -23.34 Mn |
| Mar 31, 2022 | -26.44 Mn |
| Dec 31, 2021 | -29.48 Mn |
| Sep 30, 2021 | -18.54 Mn |